Kushawaha Ajay Kishor, Jaiswal Arvind Kumar, Gupta Jay, Katiyar Sarita, Ansari Alisha, Bhatt Hemlata, Sharma Sandeep K, Choudhury Abhijit Deb, Bhatta Rabi Sankar, Singh Bhupendra N, Sashidhara Koneni V
Medicinal and Process Chemistry Division, CSIR-Central Drug Research Institute BS 10/1, Sector 10, Jankipuram Extension, Sitapur Road Lucknow 226031 India
Academy of Scientific and Innovative Research (AcSIR) Ghaziabad-201002 U.P India.
RSC Med Chem. 2024 Jul 9;15(8):2867-2881. doi: 10.1039/d4md00377b. eCollection 2024 Aug 14.
This study investigates the potential of click chemistry for the development of novel anti-tuberculosis agents. A targeted library of 1,4-dihydropyridine-1,2,3-triazole conjugates was synthesized and evaluated for their activity against HRa using the resazurin microtiter assay (REMA). Among the synthesized derivatives, compounds J10, J11, J14, J22 and J23 demonstrated significant antimycobacterial activity. These compounds exhibited low MIC values ranging from 6.24 to 6.64 μg mL, highlighting their promising potential as lead compounds for further developing novel tuberculosis therapeutics. In addition to the promising activity, structure-activity relationship (SAR) analysis revealed that electron-withdrawing groups on the aryl-substituted ring of the dihydropyridines (J10-J24), a triazole with an unsubstituted aryl ring or with electron-donating groups (methyl or methoxy), and a geminal dimethyl group are essential structural features for the observed antitubercular activity. Furthermore, ADME (absorption, distribution, metabolism, and excretion) parameters and pharmacokinetic studies supported the potential of these conjugates for oral bioavailability. These findings collectively highlight the 1,4-dihydropyridine-1,2,3-triazole scaffold as a promising platform for developing novel orally active anti-tuberculosis drugs.
本研究调查了点击化学在新型抗结核药物开发中的潜力。合成了一个1,4 - 二氢吡啶 - 1,2,3 - 三唑共轭物的靶向文库,并使用刃天青微量滴定法(REMA)评估了它们对人耐药性结核分枝杆菌(HRa)的活性。在合成的衍生物中,化合物J10、J11、J14、J22和J23表现出显著的抗分枝杆菌活性。这些化合物的最低抑菌浓度(MIC)值较低,范围为6.24至6.64μg/mL,突出了它们作为进一步开发新型结核病治疗药物的先导化合物的潜在前景。除了具有良好的活性外,构效关系(SAR)分析表明,二氢吡啶(J10 - J24)芳基取代环上的吸电子基团、具有未取代芳基环或带有供电子基团(甲基或甲氧基)的三唑以及偕二甲基是观察到的抗结核活性的关键结构特征。此外,药物吸收、分布、代谢和排泄(ADME)参数及药代动力学研究支持了这些共轭物具有口服生物利用度的潜力。这些发现共同突出了1,4 - 二氢吡啶 - 1,2,3 - 三唑支架作为开发新型口服活性抗结核药物的有前景的平台。